Alnylam Pharmaceuticals Inc. rose on promising data from an ongoing Phase 2 trial of patisiran to treat ATTR amyloidosis in patients with familial amyloidotic polyneuropathy (FAP). It is the Cambridge company’s most advanced drug and a big reason Sanofi took a 12 percent stake in Alnylam last year, the Motley Fool reports. New data show patients on patisiran had a 2.5 point decrease in an impairment score after a year, versus the usual 13- to 18-point increase for untreated patients.